Personalized ctDNA monitoring in metastatic HR+/HER2− breast cancer patients during endocrine and CDK4/6 inhibitor therapy

Abstract Improved methods to monitor treatment response may enhance patient management and clinical outcomes. This study assessed the feasibility and performance of a tumor-informed circulating tumor DNA (ctDNA) assay in metastatic HR+/HER2− breast cancer patients receiving endocrine and CDK4/6 inhi...

पूर्ण विवरण

ग्रंथसूची विवरण

मुख्य लेखकों:	Jesús Fuentes-Antrás, Mitchell J. Elliott, Sasha C. Main, Philippe Echelard, Aaron Dou, Philippe L. Bedard, Eitan Amir, Michelle B. Nadler, Nicholas Meti, Nancy Gregorio, Elizabeth Shah, Emily Van de Laar, Celeste Yu, Yangqing Deng, Lisa Gates, Clodagh Murray, Christopher G. Smith, Amber Chevalier, Scott V. Bratman, Lillian L. Siu, Hal K. Berman, David W. Cescon
स्वरूप:	Artigo
भाषा:	Inglês
प्रकाशित:	Nature Portfolio 2025-07-01
श्रृंखला:	npj Breast Cancer
ऑनलाइन पहुंच:	https://doi.org/10.1038/s41523-025-00783-2
टैग:	टैग जोड़ें कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!